Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD

Affiliations

• ¹ Department of Internal Medicine 3, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg; Erlangen, Germany, Germany.
• ² Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Germany.
• ³ Heinrich Heine University Düsseldorf, Dusseldorf, Germany.
• ⁴ Department of Internal Medicine 3, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, erlangen, Germany.
• ⁵ Department of Internal Medicine III - Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
• ⁶ Dept. of Internal Medicine III,, Regensburg, Germany.
• ⁷ University Hospital Regensburg, Regensburg, Germany.
• ⁸ Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
• ⁹ Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University; Düsseldorf, Germany.